Anti-Glomerular Basement Membrane (anti-GBM) Disease – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Anti-Glomerular Basement Membrane (anti-GBM) Disease is a rare form of small vessel vasculitis that affects the kidney and lung capillary beds. It is an archetypic autoimmune disease caused by the development of directly pathogenic autoantibodies targeting a well-characterized autoantigen expressed in the basement membranes of these organs. The body creates autoantibodies that recognize and attach to the basement membrane, part of the wall of capillary blood vessels in the kidneys and lungs. Once the autoantibodies bind to the basement membrane, this creates a signal to the body’s immune system to attack. However, the inciting events that induce the autoimmune response. Environmental factors may trigger the disease in genetically susceptible individuals, such as the current infection. Most patients develop widespread glomerular crescent formation, presenting with signs and symptoms of rapidly progressing GN, and 40%–60% will have an alveolar hemorrhage at the same time. The treatment removes pathogenic autoantibody as quickly as possible, typically with plasma exchange, steroids, and cytotoxic therapy to stop ongoing autoantibody production and tissue inflammation. The body creates autoantibodies that recognize and attach to the basement membrane, part of the wall of capillary blood vessels in the kidneys and lungs. Once the autoantibodies bind to the basement membrane, this creates a signal to the body’s immune system to attack.

 

The incidence of Anti-Glomerular Basement Membrane (anti-GBM) Disease cases ranges from 0.76 to 1.75 cases per million population in the USA.

 

The competitive landscape of Anti-Glomerular Basement Membrane (anti-GBM) Disease includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Anti-Glomerular Basement Membrane (anti-GBM) Disease across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Anti-Glomerular Basement Membrane (anti-GBM) Disease Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Anti-Glomerular Basement Membrane (anti-GBM) Disease – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. no    Asset   Company         Stage

1          Imlifidase          Hansa Biopharma AB    Phase 2

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033